While the number of notable insider purchases has slowed as the second-quarter earnings reporting season ramps up, a pair of initial public offerings in the past week tempted insiders to make huge buys.
One was a biotech and the other was an investment firm. Two other financial companies saw their chief executives offering support by picking up shares while their firms face headwinds. Let’s have a quick look at these transactions.
This post appeared first on 24/7 Wall St.